France Risks Abortion Pill Shortage Amid US Legal Battle
France risks shortages of abortion pills as US states build up stocks during an intensifying legal and political battle over reproductive rights, the country's gender equality authority has warned. This situation is particularly critical because abortion pills account for around 70 percent of pregnancy terminations in France. According to medical procedures, women take a dose of mifepristone and then a dose of misoprostol, which triggers expulsion of the embryo, 36 to 48 hours later.
Supply Chain Vulnerabilities and US Impact
France gets most of its abortion drugs from a largely US-owned manufacturer, and supplies are already under pressure from a shortage in raw materials. In addition, US states "are building up stocks to mitigate a possible halt in production or sales of mifepristone and misoprostol," France's High Council for Equality between Men and Women (HCE) said Tuesday. The organisation emphasized that "The American situation poses the risk of a shortage."
Current Medication Supply Status
- Gymiso (Misoprostol): The manufacturer Nordic Pharma warned the ANSM medicines authority late last year of production delays to this brand.
- Misoone (Misoprostol): Manufacturing of this brand has been hit by a shortage of crucial raw materials.
- Mifepristone: This drug is currently the subject of a court debate in the United States regarding its original FDA approval.
The ANSM medicines authority stated that "tensions" in supply are in the process of being resolved by distributing tens of thousands of boxes of Gymiso and having Misoone imported from Italy.
Legal Chaos and National Response
The US Supreme Court is considering the Food and Drug Administration’s approval of mifepristone more than 20 years ago, a case that has sowed legal chaos in reproductive health provision. This legal challenge follows the right-leaning Supreme Court's decision last year to overturn the Roe v. Wade ruling. In France, President Emmanuel Macron promised last month that he would soon present a law enshrining the right to abortion in the constitution.
Regarding current access, Health Minister Francois Braun insisted that it was "possible everywhere" for women to access misoprostol, telling broadcaster RMC that there are "three months of stocks" and "no shortage". However, the non-governmental Observatory for Transparency in Medication Policy (OTMeds) warned that it was difficult or impossible to get misoprostol from some pharmacies in several cities and regions, including Paris. OTMeds founder Pauline Londeix noted: "It's yet another example of how an ultra-concentrated market can put our health security at risk."